What is ferric citrate used for?

What is ferric citrate used for?

What is ferric citrate used for?

Ferric citrate is used to control the phosphorus levels in the blood of patients with chronic kidney disease (CKD) who are on dialysis. Ferric citrate is also used to treat iron deficiency anemia in patients with CKD who are not on dialysis.

Who manufactures Auryxia?

Patheon Manufacturing Services LLC
Patheon Manufacturing Services LLC of Greenville, North Carolina, a leading global provider of pharmaceutical manufacturing services, is now an FDA approved drug product manufacturer of Auryxia®.

What is Auryxia ferric citrate?

AURYXIA is a prescription medicine that can lower the amount of phosphate in the blood for adults with chronic kidney disease (CKD) who ARE on dialysis.

When was Auryxia approved?

Development Timeline for Auryxia

Date Article
Nov 7, 2017 Approval FDA Approves Auryxia (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis
Nov 17, 2014 Approval Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate

What is the generic name for Auryxia?

Generic Name: ferric citrate Ferric citrate is used to lower high blood phosphate levels in people who are on dialysis due to severe kidney disease.

Is Auryxia over the counter?

AURYXIA (ah-RICKS-ee-ah) is a prescription medicine that can lower the amount of phosphate in the blood for adults with chronic kidney disease (CKD) who are on dialysis.

What are the side effects of Auryxia?

Common side effects of Auryxia include:

  • diarrhea,
  • nausea,
  • constipation,
  • vomiting,
  • cough, and.
  • dark stools (related to the iron content).

Does Auryxia cause hyperkalemia?

Adverse Reactions Auryxia may cause diarrhea, nausea, constipation, vomiting, hyperkalemia, abdominal pain, and cough. Advise patients to report severe or persistent gastrointestinal symptoms to their physician [see ADVERSE REACTIONS].

Does Auryxia cause constipation?

Adverse reactions reported in more than 5% of patients treated with Auryxia in these trials included diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%), and cough (6%).